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Abstract 
Background: The present clinical trial study was designed to assess the effect of topical application of melatonin on 
serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and C-reactive protein (CRP) in patients 
with diabetes and periodontal disease in comparison with healthy controls. 
Material and Methods: Serum levels of TNF-α and IL-6 were measured by enzyme-linked immunosorbent assay 
and CRP by nephelometry by using the proper commercial kits in 30 patients with diabetes and periodontal disea-
se, and also in a control group of 30 healthy subjects. Periodontograms were performed using the Florida Probe®. 
Patients with diabetes were treated with a topical application of melatonin (1% orabase cream formula) once daily 
for 20 days. Healthy subjects were treated with a placebo orabase cream. 
Results: Patients with diabetes and periodontal disease had significantly higher mean levels of serum TNF-α, IL-6 
and CRP than healthy subjects (P < 0.001). Following topical melatonin application, there was a statistically signi-
ficant decrease in the gingival index and pocket depth (P < 0.001) as well as a significant decrease in IL-6 and CRP 
serum levels (P < 0.001). Local melatonin application in patients with diabetes and periodontal disease resulted in 
a significant decrease in CRP and IL-6 serum levels as well as an improvement in the gingival index and pocket 
depth. Patients with periodontal disease had significantly higher serum CRP, IL-6 and TNF-α values by comparison 
with healthy subjects. 
Conclusions: We conclude that melatonin can modulate the inflammatory action of these molecules in periodontal 
patients.
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Introduction
Periodontal disease is an inflammatory oral process 
affecting the alveolar bone, gums, and periodontal liga-
ment (1). Disease status ranges from gingivitis to advan-
ced periodontitis with destruction of connective tissue 
attachment and alveolar bone which can eventually lead 
to tooth loss (2). Periodontitis has also been associated 
with chronic inflammatory conditions including athe-
rosclerosis, cardiovascular disease, rheumatoid arthritis 
and diabetes mellitus (3-7). Although the precise rela-
tionship between systemic conditions and periodontal 
disease is still unclear, clinical evidence suggests that 
periodontitis is associated with a systemic host response 
and a low-level inflammatory state, as assessed by raised 
serum levels of systemic inflammatory markers (8,9). 
Severe periodontitis, both in patients with and without 
diabetes, has been associated with increased serum le-
vels of proinflammatory cytokines and proinflammatory 
mediators, including several interleukins (IL), such as 
IL-7, IL-6, IL-1β, tumor necrosis factor-alpha (TNF-α), 
and C-reactive protein (CRP) (4,10-15). Consequently, 
it has been suggested that periodontal disease may con-
tribute to general inflammation and the development of 
inflammatory systemic diseases (4,10-14). Furthermore, 
patients with rheumatoid arthritis receiving anti-TNF-α 
medication have better periodontal indices and lower 
levels of TNF-α within the gingival crevicular fluids, 
which indicates that suppression of proinflammatory 
cytokines might prove beneficial in suppressing perio-
dontal disease (15).
It is known that diabetes is a proinflammatory metabo-
lic disorder that increases the production of cytokines 
such as IL-6, TNF-α and IL-10 (11-14). Furthermore, it 
has been suggested that a systemic inflammatory state 
may be involved in the etiology of this illness (16,17). A 
relationship appears to exist between periodontal disea-
se and several systemic pathologies-including diabetes 
mellitus-and it could be hypothesized that controlling 
one of these two pathologies may be beneficial in con-
trolling the other (17). However, we should remember 
that periodontal disease is an infectious process with 
an inflammatory reaction that affects diabetes and gly-
caemia control. Recent studies have demonstrated that 
periodontitis itself can cause alterations that the presen-
ce of diabetes exacerbates (17). Topical application of 
melatonin improves these biochemical parameters lea-
ding us to consider melatonin is useful in treating this 
pathology (18). The immunomodulatory effects of mela-
tonin have already been established in patients with and 
without periodontal disease. A recent systematic review 
has stated that melatonin may suppress the inflammation 
of the gingiva and periodontum (19).
Melatonin is an indoleamine secreted by the pineal gland 
following a circadian pattern.
As it is highly lipophylic, melatonin reaches every cell 
in the organism, and also melatonin concentrations in sa-
liva are between 24% and 33% of those found in plasma 
joined to plasma proteins (20). A significant positive co-
rrelation between salivary and plasma melatonin exists 
and, by measuring salivary melatonin, oral pathologies 
can be studied in relation to plasma and salivary mela-
tonin behavior.
The protective role of the melatonin on the periodontal 
disease has been reported elsewhere (18,20,21). Further-
more, in a clinical study comparing patients with genera-
lized aggressive periodontitis and periodontally healthy 
subjects, nonsurgical periodontal therapy for ± 14 days 
was associated with a significant decrease in TNF-α and 
IL-17 serum levels in the group with periodontal disease 
[10]. To our knowledge, no study to date has evaluated 
the potential benefits of melatonin on TNF-α, IL-6 and 
CRP serum levels in subjects with diabetes and perio-
dontitis. Hence, a cross-sectional study was conducted 
to determine the effect of topical melatonin application 
on serum TNF-α, IL-6 and CRP concentrations in pa-
tients with diabetes and periodontal disease and in a con-
trol group of healthy subjects. 
Material and Methods 
-Participants
The study was conducted at the Healthcare Centre in 
Pinos Puente (Granada, Spain). A total of 30 healthy in-
dividuals of both sexes (20 men, 18 women), aged 31 to 
68 years (mean ± standard deviation, 47.0 ± 10.3 yrs) 
without periodontal disease and 30 patients with diabe-
tes and periodontal disease of both sexes (14 men, 16 
women) aged 24 to 58 years (mean 43.1 ± 12.4 yrs) were 
included in the study. There were 17 patients with type 1 
diabetes and 13 with type 2 diabetes (Table 1). 
All patients were free of medication (other than diabe-
tes regimens). Type of periodontal disease was not an 
inclusion criterion, although most patients presented 
advanced periodontitis (83.3%) and only 5 patients had 
mild or moderate periodontal disease. Exclusion criteria 
included current use of bisphosphonates, oral contracep-
tives, antibiotic treatment in the previous 6 months, and 
having received (within the last 6 months) or currently 
being treated for diseases of the oral cavity. All healthy 
subjects were in good general health with no history of 
systemic disease or clinical signs of periodontal disea-
se. The study was approved by the Ethics Committee 
of the Faculty of Dentistry of the University of Granada 
(Spain). Written informed consent was obtained from all 
participants.
-Study Procedures
All participants (patients and controls) underwent an 
oral examination, including medical, dental, and ca-
ries assessments. The same dentist performed all exa-
minations. Periodontograms were performed using the 
Florida Probe® handpiece (computerized periodontal 
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Patients without 
diabetes
(n=30)
Patients with 
diabetes
(n=30)
Age (years),  mean ± SD 47 ± 10.3 43.1±12.4
Women, n ( %) 18 (60%) 16 (53%)
Men, n ( %) 12 (40%) 14 (47%)
Type 1 diabetes, n (%)  17 (57%)
Type 2 diabetes, n (%)  13 (43%)
HbA1c, mean ± SD  8.43±0.89
Table 1. Description of the sample (n=60).
probing system). The gingival index and probing depth 
were recorded in patients with diabetes and in healthy 
subjects. The diagnosis for periodontal disease was ba-
sed on probing periodontal pockets ≥ 4mm.
The gingival inflammation was evaluated by probing of 
the gingival margin and observing the spontaneous blee-
ding of the gingiva. 
Thereafter, patients with diabetes were treated with a 
topical melatonin application (1% orabase cream for-
mula) in the upper and lower dental arches on attached 
gingival surfaces for 20 days. Pure melatonin was pur-
chased from Helsinn Advanced Synthesis, SA (Biasca, 
Switzerland). Melatonin 1% orabase cream formula was 
prepared by the Department of Hospital Pharmacy of the 
Hospital Perpetuo Socorro (Granada, Spain). Quality 
was certified by Methapharmaceutical Ind. (Barcelona, 
Spain). Orabase composition: Sodium Carboximetil-
celulosa16.5%; Pectin 16.5%; Jello 16.5%; Plastibase 
c.s.p.100.
Each patient was given the same kind of toothbrush, with 
the same surface, explaining each patient had to place the 
pasta with melatonin, without exceeding the limits of the 
toothbrush. The bore diameter of the tube outlet cream 
was exactly the same in all samples. The exact dosage, is 
achieved by means of a simple dispenser, applied to the 
tube outlet, which supplies a 1cc amount of melatonin 
vs. placebo preparation. 
Healthy subjects were treated with a placebo orabase 
cream. Melatonin cream (or the placebo) was applied 
daily at night after routine oral hygiene. All participants 
were instructed how to use the orabase cream. It was re-
commended they apply the amount that fits on a regular-
size adult toothbrush to each dental arch. Furthermore, 
all participants received the same brand of toothpaste 
for use during the course of the study. Conventional pe-
riodontal treatment prior to or during the study was not 
allowed. Oral examinations were also performed at the 
end of treatment (20 days after).
-Measurements of TNF-α, IL-6 and CRP Serum Con-
centrations
In all participants (patients with diabetes and periodon-
tal disease and healthy controls), blood samples were 
collected in fasting conditions at baseline and after 
treatment with melatonin or the placebo. Serum was 
separated from blood by centrifuging (10 min at 1300 
rpm), stored in aliquots at -80°C, and thawed immedia-
tely before assay. Aliquots of each sample were assayed 
using commercially available TNF-α and IL-6 sensitive 
ELISA (R & D Systems Inc., Minneapolis, MN, USA) 
in accordance with the manufacturer’s instructions. The 
lower limits of detection were 0.016 pg/mL for IL-6 and 
0.06 pg/mL for TNF-α.  The CRP concentration in serum 
was measured using nephelometry, a commercially avai-
lable latex particle-enhanced immunoassay (NA Latex 
CRP kit, Dade Behring, Tokyo, Japan).
-Plasma melatonin determination
Patients came to the laboratory at 08:00 after an over-
night fast and remained seated for 30 min before sam-
ples were taken. Blood samples were drawn from the 
antecubital vein and centrifuged at 3000 g for 10 min. 
Plasma was separated and frozen at -20ºC until analy-
sis. Plasma melatonin was determined by a commercial 
RIA (DVD Biochemie, Marburg GmbH, Germany) and 
quality control was performed showing intra- and inter-
assay coefficients of variation of 11.3% and 6.3%, res-
pectively. The recovery of added melatonin was 84.4% 
and assay sensitivity was 4.65 pg/mL.
-Statistical Analysis
Quantitative variables are expressed as mean ± standard 
deviation (SD). The paired Student’s t test was used to 
compare the gingival index and probing depth before 
and after topical application of melatonin in patients 
with diabetes and periodontal diabetic disease, and the 
Student’s t test for independent samples to compare 
TNF-α, IL-6 and CRP serum levels between patients 
with diabetes and healthy subjects. The relationship bet-
ween the gingival index and probing depth with TNF-α, 
IL-6 and CRP serum levels was assessed with Pearson’s 
correlation coefficient. Statistical significance was set at 
P < 0.05. SPSS 11.0 was used to analyze data.
Results
Comparison of TNF-α, IL-6 and CRP serum levels in 
patients with diabetes + periodontal disease and healthy 
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controls before topical treatment with melatonin is 
shown in table 2. Patients with diabetes and periodontal 
disease had significantly higher mean levels of serum 
TNF-α (1.79 ± 0.19 vs 0.82 ± 0.17 pg/mL), IL-6 (0.57 
± 0.07 vs 0.38 ± 0.05 pg/mL), and CRP (0.39 ± 0.11 vs 
0.21 ± 0.08 mg/L) by comparison with healthy subjects. 
Moreover patients with diabetes had significantly lower 
values of salivary melatonin (4.5 ± 0.81 vs 2.7 ± 0.81 pg/
mL) and plasma melatonin (13.9 ± 3.87 vs 9.7 ± 3.27 pg/
mL) than healthy subjects.
In periodontal terms, after a daily topical melatonin 
application during 20 days among diabetic+periodontal 
patients, there was a statistically significant decrease in 
the gingival index (15.84 ± 10.26 vs 5.59 ± 4.08) and 
pocket depth (28.29 ± 19.48 vs 11.90 ± 9.01). Moreover 
it was observed a significant decrease in serum levels of 
IL-6 (0.57 ± 0.07 vs 0.47 ± 0.07 pg/mL) and CRP (0.39 
± 0.11 vs 0.31 ± 0.11 mg/L). However, no significant di-
fferences were found in serum TNF-α levels before and 
after treatment with topical melatonin (Table 3). 
Furthermore, it was found that TNF-α, IL-6 and CRP 
of serum levels before and after topical melatonin 
treatment were significantly correlated with the gingival 
index and pocket depth before and after treatment (Table 
4). This means that a decrease in the gingival index and 
pocket depth was linearly proportional with the decrease 
in TNF-α, IL-6 and CRP serum levels after topical me-
latonin treatment.
Discussion
The present results confirm the beneficial effect of topi-
cal melatonin application on clinical parameters of pe-
riodontal disease, such as the gingival index and pocket 
depth. Moreover, it was confirmed that the severity of 
the periodontal disease and the serum levels TNF-α, IL-6 
and CRP were significantly correlated. Before melatonin 
treatment, serum TNF-α, IL-6 and CRP levels in diabetic 
patients with periodontal disease were significantly hig-
her than in healthy control subjects. It should be taken 
into account that human adipose tissue is a potent source 
of inflammatory interleukins that could cause a false rela-
tionship between periodontal illness and the presence of 
interleukins (22). After topical melatonin treatment, there 
was a statistically significant decrease in the gingival in-
dex and pocket depth, as well as a significant decrease 
in serum leves of IL-6 and CRP. This, together with the 
fact that the melatonin was used in topical form, supports 
our belief that the origin of the interleukins is, basically, a 
consequence of periodontal disease. The results obtained 
by using topical melatonin appear to be better than those 
obtained by other authors using nonsurgical treatment of 
periodontal disease (23). However, not all authors agree 
that treating periodontal disease reduces interleukin con-
centrations in serum (24).
The present results demonstrate that diabetic patients 
with untreated periodontitis present increased circulating 
levels of markers of inflammation and proinflammatory 
Healthy subjects (n = 30)
mean ± SD
Diabetic Patients (n = 30)
mean ± SD
P value
TNF-α, pg/mL 0.82 ± 0.17 1.79 ± 0.19 < 0.001
IL-6, pg/mL 0.38 ± 0.05 0.57 ± 0.07 < 0.001
CRP, mg/L 0.21 ± 0.08 0.39 ± 0.11 < 0.001
Table 2. Comparison of serum TNF-α, IL-6 and CRP levels in diabetic patients with periodontal disease and 
healthy controls before topical treatment with melatonin.
Table 3. Comparison of gingival index, pocket depth and TNF-α, IL-6 and CRP serum levels before 
and after topical application of melatonin in patients with diabetes and periodontal disease. 
 
 Treatment with topical melatonin for 20 days 
P-value
Before (mean ± SD) After (mean ± SD) 
Periodontal indexes    
Gingival index 15.84 ± 10.26 5.59 ± 4.08 < 0.001 
Pocket depth 28.29 ± 19.48 11.90 ± 9.01 < 0.001 
Serum levels    
TNF-Į, pg/mL 1.79 ± 0.19 1.76 ± 0.19 NS 
IL-6, pg/mL 0.57 ± 0.07 0.47 ± 0.07 < 0.001 
CRP, mg/L 0.39 ± 0.11 0.31 ± 0.11 < 0.001 
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Table 4. Correlations between gingival index, pocket depth and TNF-α, IL-6 and CRP levels in serum before and after treatment with me-
latonin in the patient group (n=30).
Gingival index Pocket depth 
Before  After Before  After 
TNF-Į, pg/mL    
Before r = 0.610, P < 0.001 r = 0.526, P = 0.003 r = 0.658, P < 0.001 r = 0.459, P = 0.01 
After r = 0.620, P < 0.001 r = 0.514, P = 0.004 r = 0.673, P < 0.001 r = 0.470, P = 0.009 
IL-6, pg/mL     
Before r = 0.569, P = 0.01 r = 0.484, P = 0.007 r = 0.609, P < 0.001 r = 0.417, P = 0.022 
After r = 0.625, P < 0.001 r = 0.523, P = 0.003 r = 0.663, P < 0.001 r = 0.461, P = 0.01 
CRP, mg/L     
Before r = 0.635, P < 0.001 r = 0.593, P = 0.001 r = 0.693, P < 0.001 r = 0.527, P = 0.003 
After r = 0.687, P < 0.001 r = 0.565, P = 0.001 r = 0.730, P < 0.001 r = 0.573, P = 0.001 
Pocket depth     
Before r = 0.943, P < 0.001 r = 0.721, P = 0.005   
After r = 0.701, P = 0.07 r = 0.684,  P = 0.009   
cytokines (CRP, TNF-α and IL-6). Over expression of 
these inflammatory mediators in serum in subjects with 
periodontal disease suggests a potential hyper-reactivity 
of cells in these individuals that may favour periodontal 
tissue breakdown and a systemic inflammatory burden. 
Elevated levels of cell-mediated and cytokine-media-
ted markers of inflammation-including CRP and other 
cytokines-are reported to be associated with periodontal 
disease (10). In systematic reviews and meta-analyses of 
CRP protein in relation to periodontitis, CRP levels were 
consistently higher in patients than in controls (25,26). 
It has been estimated that the weighted mean difference 
in CRP between patients and controls was 1.56 mg/L (p 
< 0.00001) and that the levels of CRP after periodontal 
therapy, is reduced on average 0.50 mg/L (95% confi-
dence interval [CI] 0.08-0.93) (25). Moreover, a meta-
analysis of 4 randomized clinical trials (26) estimated 
a significant reduction in CRP levels (-0.231 mg/L on 
average) after introducing periodontal treatment, which 
indicates that nonsurgical periodontal treatment had a 
positive effect on reduction of serum CRP levels. The 
present results agree with findings from both meta-
analyses, although in our study periodontal treatment 
was replaced by topical application of melatonin, the be-
neficial effect of which on periodontal disease has been 
demonstrated in previous studies (20,21,27).
The systemic levels of TNF-α in subjects with periodon-
titis and the impact of periodontal treatment on serum 
TNF-α concentrations are little understood. We found 
significantly higher TNF-α levels among patients with 
diabetes and periodontal disease than in healthy subjects 
however, the TNF-α levels before and after melatonin 
use did not change significantly, therefore this serum pa-
rameter seems to be indifferent to the periodontal chan-
ges, in contrast to that reported elsewhere (28). Higher 
levels of circulating TNF-α in patients with periodon-
titis as compared with healthy subjects have consis-
tently been reported in most studies (10,24). However, 
the effect of periodontal therapy on the systemic level 
of TNF-α has not been clarified. Mendes Duarte et al. 
(10) report that subjects with generalized aggressive pe-
riodontitis presented higher levels of circulating TNF-α 
than controls but TNF-α levels remained higher after pe-
riodontal therapy. Nakajima et al. (29) report that perio-
dontal treatment did not affect TNF-α levels 
We are aware that Type I diabetes, is more aggressive 
and could be a determining factor to the effect of mela-
toniona, but the sample size is insufficient to find signi-
ficant differences between these subgroups.
As reported elsewhere we found high levels of IL-6 in 
patients with periodontal disease when compared with 
healthy controls. The IL-6 is an important proinflamma-
tory cytokine involved in the regulation of host response 
to tissue injury and infection. It is produced by a variety 
of cells, such as monocytes, fibroblasts, osteoblasts and 
vascular endothelial cells, in response to inflammatory 
challenges (27).
Subjects included in the study were not instructed to 
change their habits of toothbrushing, therefore, we 
believe that the results are attributable to the effect of 
melatonin, but it is possible that, some subjects, change 
their oral hygiene habits when they entered the study; in 
fact, some studies show a reduction of IL-1ß, only with 
changing brushing techniques (30).
Future studies, should include positive and negative 
controls and tests, ie healthy patients with periodontitis 
and diabetic patients without periodontitis, to avoid con-
fusion of diabetes factor in the outcome (periodontitis).
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To summarize, the diabetic patients with periodontal 
disease had significantly higher serum CRP, IL-6 and 
TNF-α values by comparison with healthy subjects. Af-
ter a 20 days of daily local melatonin application in such 
diabetic patients with periodontal disease, a significant 
decrease in serum CRP and IL-6 levels as well as an 
improvement in the gingival index and pocket depth was 
observed. 
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